A Multicenter Phase 2/3 Trial of the Efficacy and Safety of Intracerebroventricular Radioimmunotherapy using 131I-burtomab for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Study Overview

The purpose of this research study is to find out about the treatment effects of an antibody called murine 8H9 (mu8H9).

Study Description

The proposed phase 2/3 international multi-center trial evaluates the efficacy and safety of intracerebroventricular 131I-burtomab as well as the dosimetry in pediatric NB patients with CNS/LM metastases. The findings of the proposed trial will expand and be compared with the findings of the single center trial of intracerebroventricular 131I-burtomab in pediatric patients with NB CNS/LM metastases treated in the MSK Trial 03-133. The aggregate findings from the two trials evaluating patients from several centers in the US as well as Europe seek to provide a basis for establishing 131I-burtomab as the next generation treatment of NB patients with CNS/LM metastases.


  • IRB Number: 1801971637 (PHO-YMABS-PRADHAN-101)
  • Research Study Identifier: TX8912
  • Principal Investigator: Terry Vik, MD

Recruitment Status

Open

Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Volunteer Sign up

Volunteer Registry

Create your profile and be matched to research opportunities

Register Now!

Contact Us

If you need help finding a study or have any questions, please contact us at inhealth@iu.edu or by phone at (888) 264-0005.